All In Biotech

Drug Trial Radar · NCT06926647

A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B

A Multicenter, Prospective, Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B

Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

May 1, 2025

Primary completion

Dec 15, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Beijing 302 HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 14, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, prospective, real-world study. The study plans to include a total of 2000 patients who meet the inclusion and exclusion criteria, consisting of 1600 treatment-naive patients and 400 treatment-experienced patients. The effectiveness and safety of different treatment strategies will be evaluated in children aged 1-12 years with treatment-naive and treatment-experienced chronic hepatitis B (CHB) and chronic HBV infection.

Conditions

  • HBV
  • Chronic Hepatitis b

Interventions

  • Nucleos(t)ide AnaloguesDrug

    Administer NAs \[LAM, ETV, TDF, TAF (TAF preferred for those aged 6 years and older)\] continuously for 48 weeks based on age.

  • Interferon alfaDrug

    IFNα monotherapy for 48 weeks (select conventional IFNα for ages ≥1 and \<3 years, select PEG-IFNα-2b for ages ≥3 years)

  • NAs combined with IFNαDrug

    Receive NAs combined with IFNα treatment for 48 weeks.

  • comparative observationOther

    Blank control observation for 48 weeks.

  • drug withdrawal observationOther

    This group is the drug withdrawal observation group, which will strictly monitor virological indicators and biochemical results, and will reinitiate antiviral treatment if necessary based on antiviral treatment standards and the willingness of the child (or family members)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HBsAg seroconversion rateTime frame: Week 48,96

Locations

85 sites in 1 country. Site status is shown where the registry gives one.

  • Ankang Central Hospital

    Ankang, China

  • Anyang Fifth People's Hospital

    Anyang, China

  • Beihai People's Hospital

    Beihai, China

  • 301 Hospital

    Beijing, China

  • Binzhou Medical University Affiliated Hospital

    Binzhou, China

  • Changzhi Medical College Affiliated Peace Hospital

    Changzhi, China

  • Changzhou Third People's Hospital

    Changzhou, China

  • Chengdu Public Health Clinical Medical Center

    Chengdu, China

  • West China Second Hospital, Sichuan University

    Chengdu, China

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, China

  • Dongguan People's Hospital

    Dongguan, China

  • Dongying People's Hospital

    Dongying, China

  • Foshan First People's Hospital

    Foshan, China

  • Southern Medical University Shunde Hospital

    Foshan, China

  • Guangzhou Medical University Affiliated Women and Children's Medical Center

    Guangzhou, China

  • The Third Affiliated Hospital of Guangzhou Medical University

    Guangzhou, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, China

  • Hainan Women and Children's Medical Center

    Haikou, China

  • Handan Infectious Disease Hospital

    Handan, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, China

  • Hepu County People's Hospital

    Hepu, China

  • Shanxian Central Hospital

    Heze, China

  • Jiangmen Traditional Chinese Medicine Hospital

    Jiangmen, China

  • Lanzhou Second People's Hospital

    Lanzhou, China

  • Tibet Autonomous Region Third People's Hospital

    Lhasa, China

  • Liaocheng People's Hospital

    Liaocheng, China

  • Linfen People's Hospital

    Linfen, China

  • Linfen Third People's Hospital

    Linfen, China

  • Liuzhou Workers' Hospital

    Liuzhou, China

  • Longyan Second Hospital

    Longyan, China

  • Luoyang Central Hospital

    Luoyang, China

  • Southwest Medical University Affiliated Hospital

    Luzhou, China

  • Jiangxi Children's Hospital

    Nanchang, China

  • Nanchang Ninth Hospital

    Nanchang, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China

  • Nanning Fourth People's Hospital

    Nanning, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, China

  • Nanyang Central Hospital

    Nanyang, China

  • Affiliated Hospital of Putian University

    Putian, China

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.